Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for PTCT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 2.229B
March 31, 2026 1.892B
December 31, 2025 1.945B
September 30, 2025 1.688B
June 30, 2025 1.989B
March 31, 2025 2.027B
December 31, 2024 1.140B
September 30, 2024 1.013B
June 30, 2024 1.093B
March 31, 2024 884.81M
December 31, 2023 876.74M
September 30, 2023 294.81M
June 30, 2023 337.94M
March 31, 2023 336.30M
December 31, 2022 410.70M
September 30, 2022 288.43M
June 30, 2022 505.54M
March 31, 2022 587.79M
December 31, 2021 773.38M
September 30, 2021 867.94M
June 30, 2021 947.08M
March 31, 2021 988.41M
December 31, 2020 1.104B
September 30, 2020 1.141B
June 30, 2020 498.89M
Date Value
March 31, 2020 595.86M
December 31, 2019 686.56M
September 30, 2019 708.65M
June 30, 2019 363.54M
March 31, 2019 407.16M
December 31, 2018 227.59M
September 30, 2018 249.40M
June 30, 2018 296.11M
March 31, 2018 178.27M
December 31, 2017 191.25M
September 30, 2017 169.31M
June 30, 2017 181.07M
March 31, 2017 202.58M
December 31, 2016 231.67M
September 30, 2016 248.34M
June 30, 2016 272.89M
March 31, 2016 298.71M
December 31, 2015 338.92M
September 30, 2015 371.52M
June 30, 2015 255.22M
March 31, 2015 280.47M
December 31, 2014 315.24M
September 30, 2014 209.39M
June 30, 2014 226.86M
March 31, 2014 246.58M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Biogen, Inc. 1.285B
BioMarin Pharmaceutical, Inc. 874.00M
Arcturus Therapeutics Holdings, Inc. 191.48M
Spruce Biosciences, Inc. 96.30M
ACADIA Pharmaceuticals, Inc. 956.47M